Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy

Natalizumab-associated PML

(2017) Nicholas Schwab et al.   NEUROLOGY

Classifying PML risk with disease modifying therapies

(2017) Joseph R. Berger   Multiple Sclerosis and Related Disorders

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study

(2017) Harald Hegen et al.   PLoS One

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

(2017) Julia Krämer et al.   PLoS One

Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: A systematic review

(2016) Marlies Weltevrede et al.   EXPERIMENTAL GERONTOLOGY

Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies

(2016) Michael Auer et al.   JOURNAL OF MEDICAL VIROLOGY

LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY

(2016) Andreas-Antonios Roussakis et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay

(2016) Marie-Sarah Gagne Brosseau et al.   NEUROLOGY

PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?

(2016) Klaus Lehmann-Horn et al.   NEUROLOGY

Fingolimod-associated PML in a patient with prior immunosuppression

(2016) Tirisham V. Gyang et al.   NEUROLOGY

Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report

(2016) Jahir Andres Miranda Acuña et al.   Multiple Sclerosis and Related Disorders

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry

(2016) Luca Prosperini et al.   PLoS One

PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate

(2015) Thorsten Rosenkranz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune aging, dysmetabolism, and inflammation in neurological diseases

(2015) Michela Deleidi et al.   Frontiers in Neuroscience

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis

(2014) Renaud A. Du Pasquier et al.   CNS DRUGS

Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?

(2014) Gary R Cutter et al.   Multiple Sclerosis Journal

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

(2013) C. Bozic et al.   EUROPEAN JOURNAL OF NEUROLOGY

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

(2013) G Francis et al.   Multiple Sclerosis Journal

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis

(2013) C. Warnke et al.   NEUROLOGY

PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section

(2013) J. R. Berger et al.   NEUROLOGY

Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain

(2012) M. W. Ferenczy et al.   CLINICAL MICROBIOLOGY REVIEWS

Missing Data

(2012) Iris Eekhout et al.   EPIDEMIOLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

(2011) Carmen Bozic et al.   ANNALS OF NEUROLOGY

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

(2011) P. Vermersch et al.   NEUROLOGY

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

(2010) Chen S Tan et al.   LANCET NEUROLOGY

Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors

(2009) Adrian Egli et al.   JOURNAL OF INFECTIOUS DISEASES

Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression

(2009) S. Gheuens et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY